Home > Insider Trading > Filing (0001818382-24-000084)

Filing Details

Accession Number:: 0001818382-24-000084
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-06-04 18:57:57
Reporting Period:: 2024-05-31

Accepted Time:: 2024-06-04 18:57:57
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1818382	Humacyte Inc.	HUMA	Biological Products, (No Disgnostic Substances) (2836)	851763759

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1878075	E Laura Niklason	2525 East North Carolina Highway 54 Durham NC 27713	President, Ceo And Director	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2024-05-31	716,573	$7.78	5,474,567	No	4	S	Indirect	By Ayabudge LLC
Common Stock	Disposition	2024-05-31	93,213	$8.93	5,381,354	No	4	S	Indirect	By Ayabudge LLC
Common Stock	Disposition	2024-06-03	190,214	$7.42	5,191,140	No	4	S	Indirect	By Ayabudge LLC
Common Stock	Disposition	2024-06-04	1,852	$7.28	5,189,288	No	4	S	Indirect	By Ayabudge LLC

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Ayabudge LLC
No	4	S	Indirect	By Ayabudge LLC
No	4	S	Indirect	By Ayabudge LLC
No	4	S	Indirect	By Ayabudge LLC

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	238,470	Direct
Common Stock	510,161	Indirect	By spouse
Common Stock	1,148,240	Indirect	By The Niklason Living Trust

Footnotes

The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.
The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $7.405 to $8.40. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
A portion of this sale is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the purchase by Dr. Niklason of 2,050 shares of the Issuer's common stock on June 3, 2024, at a price per share of $7.37. The Reporting Person has paid the Issuer $4,007.76, representing the full amount of profit realized in connection with this sale.
The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $8.41 to $9.345. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $7.25 to $7.625. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $7.265 to $7.33. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.